Valeo Pharma Stock Fundamentals
| VPHIF Stock | USD 0.05 0.00 0.00% |
Valeo Pharma fundamentals help investors to digest information that contributes to Valeo Pharma's financial success or failures. It also enables traders to predict the movement of Valeo Pink Sheet. The fundamental analysis module provides a way to measure Valeo Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Valeo Pharma pink sheet.
Valeo |
Valeo Pharma Company Return On Equity Analysis
Valeo Pharma's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Valeo Pharma Return On Equity | -16.0 |
Most of Valeo Pharma's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Valeo Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Valeo Pharma has a Return On Equity of -16.0041. This is 33.23% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The return on equity for all United States stocks is notably higher than that of the company.
Valeo Pharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Valeo Pharma's current stock value. Our valuation model uses many indicators to compare Valeo Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Valeo Pharma competition to find correlations between indicators driving Valeo Pharma's intrinsic value. More Info.Valeo Pharma is rated below average in return on equity category among its peers. It is rated fourth in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Valeo Pharma's earnings, one of the primary drivers of an investment's value.Valeo Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Valeo Pharma's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Valeo Pharma could also be used in its relative valuation, which is a method of valuing Valeo Pharma by comparing valuation metrics of similar companies.Valeo Pharma is currently under evaluation in return on equity category among its peers.
Valeo Fundamentals
| Return On Equity | -16.0 | |||
| Return On Asset | -0.26 | |||
| Profit Margin | (0.93) % | |||
| Operating Margin | (0.61) % | |||
| Current Valuation | 57.28 M | |||
| Shares Outstanding | 82.19 M | |||
| Shares Owned By Insiders | 47.72 % | |||
| Price To Book | 66.75 X | |||
| Price To Sales | 2.14 X | |||
| Revenue | 27.75 M | |||
| Gross Profit | 8.52 M | |||
| EBITDA | (19.04 M) | |||
| Net Income | (25.75 M) | |||
| Cash And Equivalents | 27.72 M | |||
| Cash Per Share | 0.34 X | |||
| Total Debt | 59.53 M | |||
| Current Ratio | 2.88 X | |||
| Book Value Per Share | (0.22) X | |||
| Cash Flow From Operations | (28.5 M) | |||
| Earnings Per Share | (0.21) X | |||
| Number Of Employees | 115 | |||
| Beta | 2.47 | |||
| Market Capitalization | 35.68 M | |||
| Total Asset | 58.27 M | |||
| Net Asset | 58.27 M |
About Valeo Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Valeo Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Valeo Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Valeo Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceutical products with primary focus on respiratory, speciality, and hospital generic products in Canada. The company was incorporated in 2003 and is headquartered in Kirkland, Canada. Valeo Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 100 people.
Currently Active Assets on Macroaxis
Other Information on Investing in Valeo Pink Sheet
Valeo Pharma financial ratios help investors to determine whether Valeo Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Valeo with respect to the benefits of owning Valeo Pharma security.